KZIA Stock Catalyst: Kazia Therapeutics Launches Clinical Trial for Paxalisib and Immunotherapy in Advanced Breast Cancer

Jan 29, 2025 · 7:03pm ET

Regulatory approval granted for the trial.

Max move

+75.0%

High of day $14.00

Sparker timei

7:03pm ET

KZIA · Jan 29, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Kazia Therapeutics Limited American Depositary Shares (KZIA) has received regulatory approval and initiated a clinical trial to evaluate the combination of Paxalisib and immunotherapy in patients with advanced breast cancer.

The trial aims to assess the efficacy and safety of this combination therapy in treating advanced breast cancer patients.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time KZIA sparks.

Download Sniper App →

Catch the next KZIA-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →